Is Innoviva (INVA) One of the Best Cheap Small Cap Stocks to Buy Now?

Innoviva, Inc. (NASDAQ:INVA) is one of the best cheap small cap stocks to buy now. Nortiva Bio, Inc., which is a wholly owned subsidiary of Innoviva, Inc. (NASDAQ:INVA), announced on June 18 its launch as a clinical-stage biopharmaceutical company dedicated to the development of long-acting oral medicines using its proprietary LYNX™ drug delivery platform. Innoviva, Inc. (NASDAQ:INVA) acquired the LYNX platform from Lyndra Therapeutics, Inc. in 2025, with the platform capable of transforming daily pills into long-acting oral therapies with single doses that last up to a month in multiple therapeutic areas. Management stated that the advancement can improve medication adherence, optimize efficacy and safety, and positively impact patients’ quality of life.

Innoviva, Inc. (INVA): Among Stocks with Insanely High PE Ratios Insiders Are Selling

It further stated that the LYNX platform is built on “foundational science from the labs of Robert Langer and Gio Traverso at MIT”, bolstered by years of clinical validation, development, and research, which includes proof of concept in multiple therapeutic areas and a successful Phase 3 study.

Innoviva, Inc. (NASDAQ:INVA) is involved in the development, commercialization, and financial management of biopharmaceuticals.

While we acknowledge the risk and potential of INVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INVA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1